Comparative immune phenotypic analysis of cutaneous squamous cell carcinoma and intraepidermal carcinoma in immune-competent individuals: Proportional representation of CD8+ T-cells but not FoxP3+ regulatory T-cells is associated with disease stage

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Freeman, Andrew ^a,b   Bridge, Jennifer A ^b   Maruthayanar, Pirashanthini ^b   Overgaard, Nana H ^b   Jung, Ji Won ^b   Simpson, Fiona ^b   Prow, Tarl W ^b   Soyer, H Peter ^b   Frazer, Ian H ^b   Freeman, Michael ^a,b   Wells, James W ^b  

^a Pindara Private Hospital   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; FOXP3+ REGULATORY T LYMPHOCYTE; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; INTRAEPIDERMAL CARCINOMA; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL; PLASMACYTOID DENDRITIC CELL; PRECANCER; REGULATORY T LYMPHOCYTE; SKIN CARCINOMA; SKIN DEFECT; STAGING; ADVERSE EFFECTS; CELL MOTION; CYTOLOGY; DISEASE COURSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHENOTYPE; RADIATION RESPONSE; SKIN; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; SUNLIGHT; VERY ELDERLY;

CD3 ANTIGEN; CD56 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; NCAM1 PROTEIN, HUMAN;

AGED; AGED, 80 AND OVER; ANTIGENS, CD11C; ANTIGENS, CD3; ANTIGENS, CD56; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HLA-DR ANTIGENS; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PHENOTYPE; SKIN; SKIN NEOPLASMS; SUNLIGHT; T-LYMPHOCYTES, REGULATORY;

EID: 84908610690     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110928     Document Type: Article

References (38)

1. Ziegler A, Jonason AS, Leffell D.J., Simon JA, Sharma HW, et al. (1994) Sunburn and p53 in the onset of skin cancer. Nature 372: 773-776.
2. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M (2004) The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clinics in dermatology 22: 189-196.
3. Dodson JM, DeSpain J, Hewett J.E., Clark DP (1991) Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Archives of dermatology 127: 1029-1031.
4. Marks R, Foley P, Goodman G., Hage BH, Selwood TS (1986) Spontaneous remission of solar keratoses: the case for conservative management. The British journal of dermatology 115: 649-655.
5. Ulrich C, Schmook T, Nindl I., Meyer T, Sterry W, et al. (2003) Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. The British journal of dermatology 149 Suppl 66: 40-42.
6. Vajdic CM, van Leeuwen MT (2009) Cancer incidence and risk factors after solid organ transplantation. International journal of cancer Journal international du cancer 125: 1747-1754.
7. Akkilic-Materna M, Massone C, Komericki P (2011) Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer. Acta dermato-venereologica 91: 432-435.
8. Hanke CW, Swanson N, Bruce S., Berman B, Kulp J, et al. (2011) Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. Journal of drugs in dermatology: JDD 10: 165-170.
9. Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M., Sterry W, et al. (2010) Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. European journal of dermatology: EJD 20: 482-488.
10. Love WE, Bernhard JD, Bordeaux JS (2009) Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Archives of dermatology 145: 1431-1438.
11. Beham A, Regauer S, Soyer H.P., Beham-Schmid C (1998) Keratoacanthoma: a clinically distinct variant of well differentiated squamous cell carcinoma. Adv Anat Pathol 5: 269-280.
12. Harnden P, Southgate J (1997) Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. J Clin Pathol 50: 1032-1033.
13. Chu PG, Lyda MH, Weiss LM (2001) Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial tumours. Histopathology 39: 9-16.
14. Hussein MR, Ahmed RA (2005) Analysis of the mononuclear inflammatory cell infiltrate in the non-tumorigenic, pre-tumorigenic and tumorigenic keratinocytic hyperproliferative lesions of the skin. Cancer biology & therapy 4: 819-821.
15. Clark RA, Chong BF, Mirchandani N, Yamanaka K., Murphy GF, et al. (2006) A novel method for the isolation of skin resident T cells from normal and diseased human skin. The Journal of investigative dermatology 126: 1059-1070.
16. Zhang S, Fujita H, Mitsui H., Yanofsky VR, Fuentes-Duculan J, et al. (2013) Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma. PLoS One 8: e62154.
17. Junankar SR, Eichten A, Kramer A., de Visser KE, Coussens LM (2006) Analysis of immune cell infiltrates during squamous carcinoma development. J Investig Dermatol Symp Proc 11: 36-43.
18. Clark RA, Huang SJ, Murphy G.F., Mollet IG, Hijnen D, et al. (2008) Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. The Journal of experimental medicine 205: 2221-2234.
19. Kosmidis M, Dziunycz P, Suarez-Farinas M, Muhleisen B., Scharer L, et al. (2010) Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients. J Immunother 33: 538-546.
20. Jang TJ (2008) Prevalence of Foxp3 positive T regulatory cells is increased during progression of cutaneous squamous tumors. Yonsei medical journal 49: 942-948.
21. Berhane T, Halliday GM, Cooke B, Barnetson RS (2002) Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 146: 810-815.
22. Smolle J, Soyer HP, Ehall R, Stettner H., Kerl H (1987) NK cell density in malignant skin tumours-a stereological study. Br J Dermatol 116: 823-829.
23. Bier H, Hoffmann T, Haas I., van Lierop A (1998) Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46: 167-173.
24. Muhleisen B, Petrov I, Gachter T., Kurrer M, Scharer L, et al. (2009) Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate. Histopathology 55: 67-76.
25. Halliday GM, Patel A, Hunt M.J., Tefany FJ, Barnetson RS (1995) Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World journal of surgery 19: 352-358.
26. Patel A, Halliday GM, Barnetson RS (1995) CD4+ T lymphocyte infiltration correlates with regression of a UV-induced squamous cell carcinoma. J Dermatol Sci 9: 12-19.
27. Peguillet I, Milder M, Louis D., Vincent-Salomon A, Dorval T, et al. (2014) High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Cancer Res 74: 2204-2216.
28. Bluth MJ, Zaba LC, Moussai D, Suarez-Farinas M, Kaporis H., et al. (2009) Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J Invest Dermatol 129: 2451-2462.
29. Carroll RP, Segundo DS, Hollowood K, Marafioti T., Clark TG, et al. (2010) Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 21: 713-722.
30. Hope CM, Grace BS, Pilkington K.R., Coates PT, Bergmann IP, et al. (2014) The immune phenotype may relate to cancer development in kidney transplant recipients. Kidney Int.
31. Fukunaga A, Khaskhely NM, Ma Y, Sreevidya C.S., Taguchi K., et al. (2010) Langerhans cells serve as immunoregulatory cells by activating NKT cells. Journal of immunology 185: 4633-4640.
32. Moodycliffe AM, Nghiem D, Clydesdale G., Ullrich SE (2000) Immune suppression and skin cancer development: regulation by NKT cells. Nature immunology 1: 521-525.
33. Mattarollo SR, Rahimpour A, Choyce A., Godfrey DI, Leggatt GR, et al. (2010) Invariant NKT cells in hyperplastic skin induce a local immune suppressive environment by IFN-gamma production. Journal of immunology 184: 1242-1250.
34. Mattarollo SR, Yong M, Gosmann C., Choyce A, Chan D, et al. (2011) NKT cells inhibit antigen-specific effector CD8 T cell induction to skin viral proteins. Journal of immunology 187: 1601-1608.
35. Watarai H, Nakagawa R, Omori-Miyake M, Dashtsoodol N., Taniguchi M (2008) Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nature protocols 3: 70-78.
36. Sarchio SN, Scolyer RA, Beaugie C, McDonald D., Marsh-Wakefield F, et al. (2014) Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer. J Invest Dermatol 134: 1091-1100.
37. Kirshenbaum AS, Goff JP, Semere T, Foster B., Scott LM, et al. (1999) Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 94: 2333-2342.
38. Parizi AC, Barbosa RL, Parizi J.L., Nai GA (2010) A comparison between the concentration of mast cells in squamous cell carcinomas of the skin and oral cavity. An Bras Dermatol 85: 811-818.